Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study supports possible role of urate in slowing Parkinson's disease progression

14.10.2009
Results confirm those of 2008 study, clinical trial is underway

By examining data from a 20-year-old clinical trial, a research team based at the MassGeneral Institute for Neurodegenerative Diseases (MGH-MIND) and Harvard School of Public Health (HSPH), has found evidence supporting the findings of their 2008 study – that elevated levels of the antioxidant urate may slow the progression of Parkinson's disease.

The report – which will appear in the December 2009 Archives of Neurology and has been released online – analyzed blood and cerebrospinal fluid samples from participants in a 1980s trail of potential Parkinson's medications, confirming the previous study's findings in a totally different group of patients.

"These results were critically important. Only now we can be reasonably sure that the slower rate of progression in patients with higher concentrations of urate is real and not a chance occurrence," says Alberto Ascherio, MD, DrPh, of HSPH, the new study's lead author.

Parkinson's disease – characterized by tremors, rigidity, difficulty walking and other symptoms – is caused by destruction of brain cells that produce the neurotransmitter dopamine. The 2008 study, which investigated the observation that healthy people with elevated but still normal urate levels have a reduced risk of developing Parkinson's, found an association between higher blood urate levels and slower disease progression in 800 participants from a previous clinical trial.

To follow up that finding, the current study reviewed information from a much earlier trial that had investigated whether the drug deprenyl, now an established treatment for Parkinson's, or doses of vitamin E would slow disease progression. The researchers analyzed samples of both blood and cerebrospinal fluid from 800 participants in the DATATOP study, conducted by the Parkinson's Study Group at centers across the U.S. and Canada, to find any association of urate levels with how quickly recently diagnosed patients progressed to the point where they needed to begin standard drug therapy.

Confirming the results of the 2008 study, they found that participants with the highest blood urate levels had a 36 percent less chance of needing to begin treatment during the two-year study period than did those with the lowest urate levels. Similar results were seen for urate levels in the cerebrospinal fluid. Also echoing last year's results, the association of urate levels with risk was robust in men but less clear in women, which may reflect the fact that few women have the high natural urate levels associated with risk reduction.

"Since cerebrospinal fluid circulates in and around the brain, the association with urate CSF levels strengthens the possibility that urate has a protective influence on the cells that degenerate in Parkinson's disease," says Michael Schwarzschild, MD, PhD, of MGH-MIND, the study's senior author. "Urate is a major antioxidant and it can protect brain cells in the lab, which makes this a compelling possibility; but we don't yet know if it's urate itself or some urate-determining factor that helps people with Parkinson's."

One unexpected observation was that the association of urate levels with disease progression was not seen in DATATOP trial participants who had received vitamin E, also a powerful antioxidant that had no effect on disease progression in the original study. The researchers speculate that vitamin E might block urate's effects or that the elevated doses in the DATATOP trial might have had a pro-oxidant effect, possibilities that need further investigation.

With the support of the Michael J. Fox Foundation, Schwarzschild and Ascherio, along with Parkinson Study Group colleagues from across the country, are conducting a multicenter Phase 2 trial at 10 centers. Enrolling 90 recently diagnosed patients, the SURE-PD trial will investigate whether treatment with the urate precursor inosine can safely increase urate levels with a goal of slowing disease progression. More information on this trial is available at http://www.pdtrials.org/en/browse/all/view/259.

"Because elevated urate levels have known health risks, including gout and kidney stones," Schwarzschild stresses, "urate elevation should only be attempted in the context of a closely monitored clinical trial in which potential benefits and risks are carefully balanced."

The current study was supported by grants from the National Institutes of Health, the Department of Defense, the RJG Foundation, the American Federation for Aging Research, the Parkinson Disease Foundation and the Parkinson Study Group. Co-authors of the Archives of Neurology paper are Kui Xu, MD, and Marsha Tennis, RN, MGH-MIND; Wayne Matson, PhD, and Mikhail Bogdanov, PhD, Veterans Administration Medical Center, Bedford, Mass.: Peter LeWitt, MD, Wayne State University School of Medicine, Detroit; Shirley Eberly, MS, Arthur Watts, Karl Keiburtz, MD, Alice Rudolph, PhD, Steven Schwid, MD, David Oakes, PhD, and Ira Shoulson, MD, University of Rochester; M. Flint Beal, MD, Cornell University; Stanley Fahn, MD, Columbia University; Connie Marras, MD, and Anthony Lang, MD, University of Toronto, and Caroline Tanner, MD, PhD, Parkinson's Institute, Sunnyvale, Calif.

Massachusetts General Hospital (www.massgeneral.org), established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of $550 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, systems biology, transplantation biology and photomedicine.

Sue McGreevey | EurekAlert!
Further information:
http://www.massgeneral.org

More articles from Health and Medicine:

nachricht Routing gene therapy directly into the brain
07.12.2017 | Boston Children's Hospital

nachricht New Hope for Cancer Therapies: Targeted Monitoring may help Improve Tumor Treatment
01.12.2017 | Berliner Institut für Gesundheitsforschung / Berlin Institute of Health (BIH)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

Im Focus: Virtual Reality for Bacteria

An interdisciplinary group of researchers interfaced individual bacteria with a computer to build a hybrid bio-digital circuit - Study published in Nature Communications

Scientists at the Institute of Science and Technology Austria (IST Austria) have managed to control the behavior of individual bacteria by connecting them to a...

Im Focus: A space-time sensor for light-matter interactions

Physicists in the Laboratory for Attosecond Physics (run jointly by LMU Munich and the Max Planck Institute for Quantum Optics) have developed an attosecond electron microscope that allows them to visualize the dispersion of light in time and space, and observe the motions of electrons in atoms.

The most basic of all physical interactions in nature is that between light and matter. This interaction takes place in attosecond times (i.e. billionths of a...

Im Focus: A transistor of graphene nanoribbons

Transistors based on carbon nanostructures: what sounds like a futuristic dream could be reality in just a few years' time. An international research team working with Empa has now succeeded in producing nanotransistors from graphene ribbons that are only a few atoms wide, as reported in the current issue of the trade journal "Nature Communications."

Graphene ribbons that are only a few atoms wide, so-called graphene nanoribbons, have special electrical properties that make them promising candidates for the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

Blockchain is becoming more important in the energy market

05.12.2017 | Event News

 
Latest News

Making fuel out of thick air

08.12.2017 | Life Sciences

Rules for superconductivity mirrored in 'excitonic insulator'

08.12.2017 | Information Technology

Smartphone case offers blood glucose monitoring on the go

08.12.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>